Amedeo Smart

Free Medical Literature Service

 

Amedeo

Biliary Tract Diseases
  Free Subscription

Articles published in
Hepatology
    March 2024
  1. JONES DE, Beuers U, Bonder A, Carbone M, et al
    Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?
    Hepatology. 2024 Mar 22. doi: 10.1097/HEP.0000000000000864.
    >> Share

  2. LAL BB, Alam S, Sibal A, Kumar K, et al
    Genotype correlates with clinical course and outcome of children with tight junction protein 2 (TJP2) deficiency-related cholestasis.
    Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000828.
    >> Share

  3. AMPUERO J, Lucena A, Berenguer M, Hernandez-Guerra M, et al
    Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy.
    Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000826.
    >> Share

  4. PANDURANGI S, Mourya R, Nalluri S, Fei L, et al
    Diagnostic accuracy of serum matrix metalloproteinase-7 as a biomarker of biliary atresia in a large North American cohort.
    Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000827.
    >> Share

  5. ZHUANG Y, Szabo G
    Reply to: How does bile acid-induced IRF3 phosphorylation mediate cholestatic liver and kidney injury? more need to be known.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000816.
    >> Share

  6. KELLERER M, Javed S, Casar C, Will N, et al
    Antagonistic effects of the cytotoxic molecules granzyme B and TRAIL in the immunopathogenesis of sclerosing cholangitis.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000830.
    >> Share

  7. JIANG L, Yang Z
    Letter to the Editor: How does bile acid-induced IRF3 phosphorylation mediate cholestatic liver and kidney injury? ---more need to be known.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000813.
    >> Share

  8. LUNDBERG BAVE A, von Seth E, Ingre M, Nordenvall C, et al
    Autoimmune diseases in primary sclerosing cholangitis and their first-degree relatives.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000823.
    >> Share

    February 2024
  9. ZHANG H, Zhu K, Zhang R, Guo Y, et al
    Oleic acid-PPARgamma-FABP4 loop fuels cholangiocarcinoma colonization in lymph node metastases microenvironment.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000784.
    >> Share

    January 2024
  10. WILBUR HC, Soares HP, Azad NS
    Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations.
    Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000760.
    >> Share

  11. BARGELLINI I, Rimassa L, Masi G
    SIRT and chemotherapy in unresectable iCCA: Ready to take off.
    Hepatology. 2024;79:9-11.
    >> Share

  12. CORPECHOT C, Lemoinne S, Soret PA, Hansen B, et al
    Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
    Hepatology. 2024;79:39-48.
    >> Share

    December 2023
  13. CORPECHOT C, Lemoinne S, Soret PA, Chazouilleres O, et al
    Reply: Improving access to transient elastography data for Real-World Prognostic Applications in primary biliary cholangitis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000746.
    >> Share

  14. WIEGAND J, Franke A, Stein K, Trautwein C, et al
    Letter to the Editor: Improving access to transient elastography data for real-world prognostic applications in primary biliary cholangitis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000744.
    >> Share

  15. KREMER AE, Mayo MJ, Hirschfield GM, Levy C, et al
    Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary biliary cholangitis.
    Hepatology. 2023 Dec 20. doi: 10.1097/HEP.0000000000000728.
    >> Share

    November 2023
  16. GHOSH S, Devereaux MW, Liu C, Sokol RJ, et al
    LRH-1 agonist DLPC through STAT6 promotes macrophage polarization and prevents parenteral nutrition associated cholestasis in mice.
    Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000690.
    >> Share

  17. GEHL V, O'Rourke CJ, Andersen JB
    Immunogenomics of cholangiocarcinoma.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000688.
    >> Share

  18. HE S, Peng Y, Wei Q
    Letter to the Editor: Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: First report of the IAIHG retrospective registry.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000685.
    >> Share

  19. SLOOTER CD, van den Brand FF, Lleo A, Liberal R, et al
    Reply - Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000689.
    >> Share

  20. LIU ZP, Sun XH, Yu C, Yin XY, et al
    Letter to the Editor: How to define the futile outcome in patients undergoing surgery for perihilar cholangiocarcinoma?
    Hepatology. 2023 Nov 7. doi: 10.1097/HEP.0000000000000651.
    >> Share

  21. NIKNEJAD N, Fox D, Burwinkel JL, Zarrin-Khameh N, et al
    ASO silencing of a glycosyltransferase, Poglut1 , improves the liver phenotypes in mouse models of Alagille syndrome.
    Hepatology. 2023;78:1337-1351.
    >> Share

  22. YANG F, Hilakivi-Clarke L, Shaha A, Wang Y, et al
    Metabolic reprogramming and its clinical implication for liver cancer.
    Hepatology. 2023;78:1602-1624.
    >> Share

    October 2023
  23. RATTI F, Marino R, Groot Koerkamp B, Aldrighetti L, et al
    Reply: "How to define the futile outcome in patients undergoing surgery for perihilar cholangiocarcinoma".
    Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000659.
    >> Share

  24. SELLERS ZM, Assis DN, Paranjape SM, Sathe M, et al
    Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations.
    Hepatology. 2023 Oct 26. doi: 10.1097/HEP.0000000000000646.
    >> Share

  25. HU YF, Ma WJ, Jin YW, Li FY, et al
    Adjuvant chemotherapy for resected biliary tract cancers: A fluorouracil-based scheme beats out a gemcitabine-based scheme for the win.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000634.
    >> Share


  26. Erratum: Modulation of the tryptophan hydroxylase 1/monoamine oxidase-A/5-hydroxytryptamine/5-hydroxytryptamine receptor 2A/2B/2C axis regulates biliary proliferation and liver fibrosis during cholestasis.
    Hepatology. 2023;78:E86.
    >> Share

    September 2023
  27. GELLERT-KRISTENSEN H, Bojesen SE, Tybjaerg-Hansen A, Stender S, et al
    Telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma in 63,272 individuals from the general population.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000608.
    >> Share

  28. ZHUANG Y, Ortega-Ribera M, Thevkar Nagesh P, Joshi R, et al
    Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000611.
    >> Share

  29. SLOOTER CD, van den Brand FF, Lleo A, Colapietro F, et al
    Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
    Hepatology. 2023 Sep 4. doi: 10.1097/HEP.0000000000000589.
    >> Share

    August 2023
  30. PEISELER M, Tacke F
    Bile duct-associated macrophages enter the spotlight in inflammatory cholestatic liver disease.
    Hepatology. 2023 Aug 22. doi: 10.1097/HEP.0000000000000576.
    >> Share

  31. RATTI F, Marino R, Olthof PB, Pratschke J, et al
    Predicting futility of upfront surgery in perihilar cholangiocarcinoma: Machine learning analytics model to optimize treatment allocation.
    Hepatology. 2023 Aug 3. doi: 10.1097/HEP.0000000000000554.
    >> Share

  32. DE MUYNCK K, Heyerick L, De Ponti FF, Vanderborght B, et al
    Osteopontin characterizes bile duct associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis.
    Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000557.
    >> Share

  33. BOWLUS CL, Levy C
    Optimizing treatment of primary biliary cholangitis: Is good, good enough?
    Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000556.
    >> Share

    July 2023
  34. ZHAO L, Liu J, Li K, Zhang C, et al
    PTPN9 dephosphorylates FGFR2pY656/657 via interaction with ACAP1 and ameliorates pemigatinib effect in cholangiocarcinoma.
    Hepatology. 2023 Jul 27. doi: 10.1097/HEP.0000000000000552.
    >> Share

  35. LI Y, Li B, Xiao X, Qian Q, et al
    Itaconate inhibits CD103+ TRM cells and alleviates hepatobiliary injury in mouse models of primary sclerosing cholangitis.
    Hepatology. 2023 Jul 26. doi: 10.1097/HEP.0000000000000549.
    >> Share

  36. EDELINE J, Bridgewater J, Campillo-Gimenez B, Neveu E, et al
    Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trials.
    Hepatology. 2023 Jul 25. doi: 10.1097/HEP.0000000000000544.
    >> Share


  37. Retraction: Altered store operated calcium entry increases cyclic 3',5'-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes.
    Hepatology. 2023 Jul 21. doi: 10.1097/HEP.0000000000000484.
    >> Share

  38. JEONG H, Yoo C
    Reply: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial - author's reply.
    Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000535.
    >> Share

  39. HU YF, Gu HF, Jin YW, Li FY, et al
    Letter to the Editor: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial.
    Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000532.
    >> Share

    June 2023
  40. SOKOL RJ, Gonzales EM, Kamath BM, Baker A, et al
    Predictors of 6-year event-free survival in alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor.
    Hepatology. 2023 Jun 7. doi: 10.1097/HEP.0000000000000502.
    >> Share

  41. EKSER B, Sucu S, Mihaylov P, Emamaullee JA, et al
    Letter to the Editor mucosal gut microbiota in primary sclerosing cholangitis before and after liver transplantation: Are there other challenges?
    Hepatology. 2023 Jun 5. doi: 10.1097/HEP.0000000000000503.
    >> Share

    May 2023
  42. NEJAK-BOWEN K, Monga SP
    Wnt-beta-catenin in hepatobiliary homeostasis, injury, and repair.
    Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000495.
    >> Share


  43. Erratum: IL-6-induced cGGNBP2 encodes a protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
    Hepatology. 2023 May 15. doi: 10.1097/HEP.0000000000000040.
    >> Share

  44. SHU L, Li X, Liu Z, Li K, et al
    Bile exosomal miR-182/183-5p increases cholangiocarcinoma stemness and progression by targeting HPGD and increasing PGE2 generation.
    Hepatology. 2023 May 5. doi: 10.1097/HEP.0000000000000437.
    >> Share

  45. JEONG H, Kim KP, Jeong JH, Hwang DW, et al
    Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial.
    Hepatology. 2023;77:1540-1549.
    >> Share

  46. FORMAN LM, Sapisochin G, Assis DN, Arrive L, et al
    Reply: Living donor liver transplantation for people with PSC.
    Hepatology. 2023;77:E97-E98.
    >> Share

    April 2023
  47. MACKOWIAK B, Gao B
    Activation of cholangiocyte mTORC1 drives alcohol-induced ductular reaction.
    Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000416.
    >> Share

  48. RUSSI AE, Shivakumar P, Luo Z, Bezerra J, et al
    Plasticity between ILC2 subsets and amphiregulin expression regulate epithelial repair in biliary atresia.
    Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000418.
    >> Share

  49. DANIEL N, Genua F, Jenab M, Mayen AL, et al
    The role of the gut microbiome in the development of hepatobiliary cancers.
    Hepatology. 2023 Apr 15. doi: 10.1097/HEP.0000000000000406.
    >> Share

  50. HARTL L, Reiberger T, Trauner M
    Reply: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
    Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000399.
    >> Share

  51. UMAR S, Nadeem A, Nadeem M
    Letter to the editor: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
    Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000398.
    >> Share

  52. HIRSCHFIELD GM, Shiffman ML, Gulamhusein A, Kowdley KV, et al
    Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
    Hepatology. 2023 Apr 6. doi: 10.1097/HEP.0000000000000395.
    >> Share

  53. YOO C, Javle MM, Verdaguer Mata H, de Braud F, et al
    Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000365.
    >> Share

  54. CABALLERO-CAMINO FJ, Rodrigues PM, Wangsell F, Agirre-Lizaso A, et al
    A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multi-organ activity and shows translational relevance to humans.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000376.
    >> Share

  55. SINGH SP, Mondia N
    Letter to the Editor: Much more needed in natural history of Alagille syndrome.
    Hepatology. 2023;77:E78.
    >> Share

    March 2023
  56. HARTMANN P, Schnabl B
    Can a mucosal microbiota signature predict disease severity, survival, and disease recurrence in PSC?
    Hepatology. 2023;77:709-711.
    >> Share

    February 2023
  57. MAMMADOV RA, Visseren T, Roest HP, van der Laan LJW, et al
    Letter to Editor: the mucosal gut signature in primary sclerosing cholangitis before and after liver transplantation. is the dysbiosis index really predictive for the recurrence of psc?
    Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000338.
    >> Share

  58. LI J, Chen J, Lee PMY, Zhang J, et al
    Familial clustering of intrahepatic cholestasis of pregnancy: A nationwide population-based study in Denmark.
    Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000328.
    >> Share

  59. HOLE MJ, Kaasen Jorgensen K, Holm K, Braadland PR, et al
    Reply: The mucosal gut signature in primary sclerosing cholangitis before and after liver transplantation. Is the dysbiosis index really predictive for the recurrence of PSC?
    Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000340.
    >> Share

  60. ZHANG J, Lyu Z, Li B, You Z, et al
    P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases.
    Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000317.
    >> Share

  61. KUNDU D, Kennedy L, Zhou T, Ekser B, et al
    p16 INK4A drives non-alcoholic fatty liver disease phenotypes in high fat diet fed mice via biliary e2f1/foxo1/igf-1 signaling.
    Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000307.
    >> Share

  62. WU N, Zhou T, Carpino G, Baiocchi L, et al
    Prolonged administration of a secretin receptor antagonist inhibits biliary senescence and liver fibrosis in Mdr2-/- mice.
    Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000310.
    >> Share

  63. AMENT CE, Steinmann S, Evert K, Pes GM, et al
    Aberrant fucosylation sustains the NOTCH and EGFR/NF-kB pathways and has a prognostic value in human intrahepatic cholangiocarcinoma.
    Hepatology. 2023 Feb 16. doi: 10.1097/HEP.0000000000000322.
    >> Share

  64. VANDRIEL SM, Li LT, She H, Wang JS, et al
    Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study.
    Hepatology. 2023;77:512-529.
    >> Share

  65. HABASH N, Ibrahim SH
    The Global Alagille Alliance study: Redefining the natural history of Alagille syndrome.
    Hepatology. 2023;77:347-349.
    >> Share

    January 2023
  66. ALI AH, Buness CW, Fischer R, Holtmann GJ, et al
    Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis.
    Hepatology. 2023 Jan 30. doi: 10.1097/HEP.0000000000000304.
    >> Share

  67. BOWLUS CL, Arrive L, Bergquist A, Deneau M, et al
    Reply: insurance should cover vancomycin for primary sclerosing cholangitis.
    Hepatology. 2023 Jan 26. doi: 10.1097/HEP.0000000000000305.
    >> Share

  68. LAMARCA A, Edeline J
    Adjuvant treatment for biliary tract tumours: lost in a maze?
    Hepatology. 2023 Jan 23. doi: 10.1097/HEP.0000000000000301.
    >> Share

  69. LI Y, Yang B, Miao H, Liu L, et al
    Nicotinamide N-methyltransferase promotes M2 macrophage polarization by IL6 and MDSC conversion by GM-CSF in gallbladder carcinoma.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000028.
    >> Share

  70. UNALP-ARIDA A, Ruhl CE
    Increasing gallstone disease prevalence and associations with gallbladder and biliary tract mortality in the United States.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000264.
    >> Share

  71. GUILLOT A, Winkler M, Silva Afonso M, Aggarwal A, et al
    Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000270.
    >> Share

  72. SHORT C, Zhong A, Xu J, Mahdi E, et al
    TWEAK/FN14 promotes profibrogenic pathway activation in Prominin-1-expressing hepatic progenitor cells in biliary atresia.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000026.
    >> Share

  73. LEE SH, So J, Shin D
    Hepatocyte-to-cholangiocyte conversion occurs through transdifferentiation independently of proliferation in zebrafish.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000016.
    >> Share

  74. ZHANG L, Pan Q, Zhang L, Xia H, et al
    Runt-related transcription factor-1 ameliorates bile acid-induced hepatic inflammation in cholestasis through JAK/STAT3 signaling.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000041.
    >> Share

  75. HELLEN DJ, Bennett A, Malla S, Klindt C, et al
    Liver-restricted deletion of the biliary atresia candidate gene Pkd1l1 causes bile duct dysmorphogenesis and ciliopathy.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000029.
    >> Share

  76. NYHOLM I, Hukkinen M, Pihlajoki M, Davidson JR, et al
    Serum FGF19 predicts outcomes of Kasai portoenterostomy in biliary atresia.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000048.
    >> Share

  77. MA J, Yang Z, Huang Z, Li L, et al
    Rngtt governs biliary-derived liver regeneration initiation by transcriptional regulation of mTORC1 and Dnmt1 in zebrafish.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000186.
    >> Share

  78. CANTALLOPS VILA P, Ravichandra A, Agirre Lizaso A, Perugorria MJ, et al
    Heterogeneity, crosstalk and targeting of cancer associated fibroblasts in cholangiocarcinoma.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000206.
    >> Share

  79. HEINEMANN M, Adam R, Karam V, Schramm C, et al
    Letter to the Editor: Living donor liver transplantation for people with PSC.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000208.
    >> Share

    September 2022
  80. BORAD MJ, Bai LY, Richards D, Mody K, et al
    Silmitasertib Plus Gemcitabine and Cisplatin First-Line Therapy in Locally Advanced/Metastatic Cholangiocarcinoma: a Phase 1b/2 Study.
    Hepatology. 2022 Sep 24. doi: 10.1002/hep.32804.
    >> Share

  81. HARPAVAT S, Hawthorne K, Setchell KDR, Narvaez Rivas M, et al
    Serum Bile Acids as a New Prognostic Biomarker in Biliary Atresia Following Kasai Portoenterostomy.
    Hepatology. 2022 Sep 21. doi: 10.1002/hep.32800.
    >> Share

  82. BIAGIOLI M, Marchiano S, di Giorgio C, Roselli R, et al
    Combinatorial targeting of GPBAR1 and CYSLTR1 reveals a mechanistic role for bile acids and leukotrienes in drug induced liver injury.
    Hepatology. 2022 Sep 15. doi: 10.1002/hep.32787.
    >> Share

  83. BOWLUS CL, Arrive L, Bergquist A, Deneau M, et al
    AASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma.
    Hepatology. 2022 Sep 9. doi: 10.1002/hep.32771.
    >> Share

  84. LEUNG DH, Devaraj S, Goodrich NP, Chen X, et al
    Serum Biomarkers Correlated with Liver Stiffness Assessed in a Multi-center Study of Pediatric Cholestatic Liver Disease.
    Hepatology. 2022 Sep 7. doi: 10.1002/hep.32777.
    >> Share

  85. HOLE MJ, Kaasen Jorgensen K, Holm K, Braadland PR, et al
    A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation.
    Hepatology. 2022 Sep 3. doi: 10.1002/hep.32773.
    >> Share

    August 2022
  86. MAYO MJ
    Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?
    Hepatology. 2022;76:518-531.
    >> Share

  87. ZHANG X, Wang Z, Tang W, Wang X, et al
    Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics.
    Hepatology. 2022;76:317-329.
    >> Share

    July 2022
  88. HEUCKE N, Keitel V
    COVID-19-associated cholangiopathy: What's left after the virus has gone?
    Hepatology. 2022 Jul 13. doi: 10.1002/hep.32668.
    >> Share

  89. HARTL L, Reiberger T, Trauner M
    On the development of secondary sclerosing cholangitis in chronic liver disease patients after COVID-19.
    Hepatology. 2022 Jul 12. doi: 10.1002/hep.32664.
    >> Share

    June 2022
  90. DENG M, Ran P, Chen L, Wang Y, et al
    Proteogenomic Characterization of Cholangiocarcinoma.
    Hepatology. 2022 Jun 18. doi: 10.1002/hep.32624.
    >> Share


  91. Retracted: Posttranslational regulation of polycystin-2 protein expression as a novel mechanism of cholangiocyte reaction and repair from biliary damage.
    Hepatology. 2022 Jun 17. doi: 10.1002/hep.32595.
    >> Share

  92. XU J, Wang Y, Khoshdeli M, Peach M, et al
    IL-31 Levels Correlate with Pruritus in Patients with Cholestatic and Metabolic Liver Diseases and is FXR Responsive in NASH.
    Hepatology. 2022 Jun 10. doi: 10.1002/hep.32599.
    >> Share

    May 2022
  93. HARTL L, Haslinger K, Angerer M, Semmler G, et al
    Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in chronic liver disease patients.
    Hepatology. 2022 May 21. doi: 10.1002/hep.32582.
    >> Share

  94. SMIRNOVA E, Muthiah MD, Narayan N, Siddiqui MS, et al
    Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD.
    Hepatology. 2022 May 13. doi: 10.1002/hep.32568.
    >> Share

  95. ANDERSEN JB
    Stromal yin-yang of myofibroblasts and endothelial cells in the progression of intrahepatic cholangiocarcinoma.
    Hepatology. 2022 May 3. doi: 10.1002/hep.32558.
    >> Share

  96. ZHOU J, Sun Y, Zhang W, Yuan J, et al
    Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis.
    Hepatology. 2022 May 1. doi: 10.1002/hep.32548.
    >> Share

    April 2022
  97. JIANG ST, Zhang L, Xu YY, Lu X, et al
    Letter to the editor: For the core set of bile lipidome and meta-proteome signature, repeatability is the key.
    Hepatology. 2022 Apr 28. doi: 10.1002/hep.32543.
    >> Share

  98. SHARMA N, Yadav M, Tripathi G, Mathew B, et al
    Response to Letter to the editor: For the core set of bile lipidome and meta-proteome signature, repeatability is the key.
    Hepatology. 2022 Apr 28. doi: 10.1002/hep.32541.
    >> Share

  99. SHCHEYNIKOV N, Boggs K, Green A, Feranchak AP, et al
    Identification of the Chloride Channel, Leucine-Rich Repeat-Containing Protein 8, subfamily A (LRRC8A), in Mouse Cholangiocytes.
    Hepatology. 2022 Apr 21. doi: 10.1002/hep.32536.
    >> Share

  100. MOHAMAD ZAKI NH, Shiota J, Calder AN, Keeley TM, et al
    C-X-C motif chemokine ligand 1 induced by Hedgehog signaling promotes mouse extrahepatic bile duct repair after acute injury.
    Hepatology. 2022 Apr 7. doi: 10.1002/hep.32492.
    >> Share

  101. MANDATO C, Vajro P
    Letter to the Editor: The burgeoning field of Progressive Familial Intrahepatic Cholestasis.
    Hepatology. 2022 Apr 5. doi: 10.1002/hep.32489.
    >> Share

    March 2022
  102. SHARMA N, Yadav M, Tripathi G, Mathew B, et al
    Bile multi-omics analysis classifies lipid species and microbial peptides predictive of Carcinoma of Gall bladder.
    Hepatology. 2022 Mar 31. doi: 10.1002/hep.32496.
    >> Share

  103. JAVITT NB
    Letter to the Editor: Hyperosmolarity during hepatic bile formation:Overlooked significance.
    Hepatology. 2022 Mar 29. doi: 10.1002/hep.32482.
    >> Share

  104. HENGSTLER JG, Oude Elferink R, van de Graaf SF, Drasdo D, et al
    The de-micellization hypothesis of water influx into bile ducts.
    Hepatology. 2022 Mar 28. doi: 10.1002/hep.32485.
    >> Share

  105. WANG T, Xu C, Zhang Z, Wu H, et al
    Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression.
    Hepatology. 2022 Mar 27. doi: 10.1002/hep.32483.
    >> Share

  106. BASS LM, Ye W, Hawthorne K, Leung DH, et al
    The Risk of Variceal Hemorrhage and Pre-Transplant Mortality in Children with Biliary Atresia.
    Hepatology. 2022 Mar 10. doi: 10.1002/hep.32451.
    >> Share


  107. Erratum for Nevi, et al. DCLK1, a putative stem cell marker in human cholangiocarcinoma.
    Hepatology. 2022;75:773.
    >> Share

  108. IBRAHIM SH, Kamath BM, Loomes KM, Karpen SJ, et al
    Cholestatic Liver Diseases of Genetic Etiology: Advances and Controversies.
    Hepatology. 2022 Mar 1. doi: 10.1002/hep.32437.
    >> Share

    February 2022
  109. WU MJ, Shi L, Merritt J, Zhu AX, et al
    Biology of IDH Mutant Cholangiocarcinoma.
    Hepatology. 2022 Feb 28. doi: 10.1002/hep.32424.
    >> Share

  110. ROBERTS SB, Hirschfield GM, Worobetz LJ, Vincent C, et al
    Ethnicity, disease severity and survival in Canadian patients with Primary Biliary Cholangitis.
    Hepatology. 2022 Feb 26. doi: 10.1002/hep.32426.
    >> Share

  111. CHAUDHRY HUR, Hayat A, Ahmad A
    Letter to the Editor: Association Between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: A Swedish Population-Based Cohort Study.
    Hepatology. 2022 Feb 19. doi: 10.1002/hep.32416.
    >> Share

  112. JEON Y, Kwon SM, Rhee H, Yoo JE, et al
    Molecular and radio-pathologic spectrum between hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Hepatology. 2022 Feb 5. doi: 10.1002/hep.32397.
    >> Share

  113. LUO C, Xin H, Zhou Z, Hu Z, et al
    Tumor-Derived Exosomes Induce Immunosuppressive Macrophages to Foster Intrahepatic Cholangiocarcinoma Progression.
    Hepatology. 2022 Feb 2. doi: 10.1002/hep.32387.
    >> Share

  114. YANG Y, Choi J, Chen Y, Invernizzi P, et al
    E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants.
    Hepatology. 2022;75:266-279.
    >> Share

    January 2022
  115. RUIZ DE GAUNA M, Biancaniello F, Gonzalez-Romero F, Rodrigues PM, et al
    Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids.
    Hepatology. 2022 Jan 14. doi: 10.1002/hep.32344.
    >> Share

  116. ANDERSSON ER
    Outside influence: the extrahepatic duct as a source for bile duct regeneration.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32334.
    >> Share

  117. SHIODE Y, Kodama T, Shigeno S, Murai K, et al
    Traf3 inactivation promotes the development of intrahepatic cholangiocarcinoma via NIK-mediated hepatocyte transdifferentiation.
    Hepatology. 2022 Jan 7. doi: 10.1002/hep.32317.
    >> Share


  118. Retracted: Immunoglobulin G4(+) B-cell receptor clones distinguish immunoglobulin G4-related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies.
    Hepatology. 2022 Jan 7. doi: 10.1002/hep.32246.
    >> Share

    December 2021
  119. PASTOR CM
    Reply to the review <>.
    Hepatology. 2021 Dec 27. doi: 10.1002/hep.32296.
    >> Share

  120. VARTAK N, Hengstler JG
    REPLY TO HEP-21-2202: Analysis and limits of detection of biliary flux.
    Hepatology. 2021 Dec 25. doi: 10.1002/hep.32297.
    >> Share

  121. MASYUK AI, Masyuk TV, Trussoni CE, Pirius NE, et al
    Autophagy Promotes Hepatic Cystogenesis in Polycystic Liver Disease via Depletion of Cholangiocyte Ciliogenic Proteins.
    Hepatology. 2021 Dec 23. doi: 10.1002/hep.32298.
    >> Share

  122. REMETIC J, Ghallab A, Hobloss Z, Brackhagen L, et al
    Loss of bile salt export pump aggravates lipopolysaccharide-induced liver injury in mice due to impaired hepatic endotoxin clearance.
    Hepatology. 2021 Dec 20. doi: 10.1002/hep.32289.
    >> Share

  123. SAPISOCHIN G, Ivanics T, Heimbach J
    Liver Transplantation for intrahepatic cholangiocarcinoma: ready for prime time?
    Hepatology. 2021 Dec 3. doi: 10.1002/hep.32258.
    >> Share

    November 2021
  124. RUBINO JG, Flemming JA
    Menopausal hormone therapy and risk of biliary tract cancers: addressing the ant, not the elephant in the room.
    Hepatology. 2021 Nov 25. doi: 10.1002/hep.32254.
    >> Share

  125. JACKSON SS, Pfeiffer RM, Gabbi C, Anderson L, et al
    Menopausal hormone therapy and risk of biliary tract cancers.
    Hepatology. 2021 Nov 11. doi: 10.1002/hep.32198.
    >> Share

  126. LI H, Lan T, Liu H, Liu C, et al
    IL-6 induced cGGNBP2 encodes a novel protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
    Hepatology. 2021 Nov 10. doi: 10.1002/hep.32232.
    >> Share

  127. WU N, Carpino G, Ceci L, Baiocchi L, et al
    MT1 but not MT2 melatonin receptor knockout decreases biliary damage and liver fibrosis during cholestatic liver injury.
    Hepatology. 2021 Nov 7. doi: 10.1002/hep.32233.
    >> Share

  128. LEE BT, Tana MM, Kahn JA, Dara L, et al
    We Are Not Immune: Racial and Ethnic Disparities in Autoimmune Liver Diseases.
    Hepatology. 2021;74:2876-2887.
    >> Share

    October 2021
  129. ZIMMER CL, Filipovic I, Cornillet M, O'Rourke CJ, et al
    MAIT cell tumor infiltration predicts long-term survival in cholangiocarcinoma.
    Hepatology. 2021 Oct 30. doi: 10.1002/hep.32222.
    >> Share

  130. KONIGSHOFER P, Hofer BS, Brusilovskaya K, Simbrunner B, et al
    Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies.
    Hepatology. 2021 Oct 30. doi: 10.1002/hep.32220.
    >> Share

  131. LINDOR KD, Dawson PA, Trauner M
    Alan Hofmann (1931-2021): A Career Well Spent Understanding Bile Acids.
    Hepatology. 2021 Oct 18. doi: 10.1002/hep.32206.
    >> Share

  132. FAIRFIELD CJ, Drake TM, Pius R, Bretherick AD, et al
    Genome-wide Analysis Identifies Novel Gallstone-susceptibility Loci Including Genes Regulating Gastrointestinal Motility.
    Hepatology. 2021 Oct 15. doi: 10.1002/hep.32199.
    >> Share

  133. GRAHAM JJ, Mukherjee S, Yuksel M, Sanabria Mateos R, et al
    Aberrant hepatic trafficking of gut-derived T-cells is not specific to primary sclerosing cholangitis.
    Hepatology. 2021 Oct 11. doi: 10.1002/hep.32193.
    >> Share

  134. CHEN L, Yang H, Li H, He C, et al
    Novel insights into modifiable risk factors of cholelithiasis: A Mendelian randomization study.
    Hepatology. 2021 Oct 8. doi: 10.1002/hep.32183.
    >> Share

  135. LLEO A, Hirschfield GM
    Letter to the Editor: Are We Confident That Primary Biliary Cholangitis Liver-Related Mortality Is Higher in Males?
    Hepatology. 2021;74:2307.
    >> Share

  136. MA Y, Su H, Yuksel M, Longhi MS, et al
    Human Leukocyte Antigen Profile Predicts Severity of Autoimmune Liver Disease in Children of European Ancestry.
    Hepatology. 2021;74:2032-2046.
    >> Share

    September 2021
  137. ZHAO C, Lancman JJ, Yang Y, Gates KP, et al
    Intrahepatic cholangiocyte regeneration from an Fgf-dependent extrahepatic progenitor niche in a zebrafish model of Alagille Syndrome.
    Hepatology. 2021 Sep 27. doi: 10.1002/hep.32173.
    >> Share

  138. HUNG HY, Wang CC, Wei JC
    Letter to the Editor: Postdiagnosis aspirin use associated with decreased biliary tract cancer?
    Hepatology. 2021 Sep 23. doi: 10.1002/hep.32170.
    >> Share

  139. VARTAK N, Hengstler JG
    Response to 21-1766: Challenging the dogma of canalicular bile flow.
    Hepatology. 2021 Sep 21. doi: 10.1002/hep.32168.
    >> Share

  140. ZHOU SL, Luo CB, Song CL, Zhou ZJ, et al
    Genomic evolution and the impact of SLIT2 mutation in relapsed intrahepatic cholangiocarcinoma.
    Hepatology. 2021 Sep 20. doi: 10.1002/hep.32164.
    >> Share

  141. JAVITT NB, Boyer JL
    Letter to the Editor: On the Mechanisms of Biliary Flux.
    Hepatology. 2021 Sep 20. doi: 10.1002/hep.32167.
    >> Share

  142. DE JONG IEM, Overi D, Carpino G, Gouw ASH, et al
    Persistent Biliary Hypoxia and Lack of Regeneration Are Key Mechanisms in the Pathogenesis of Post-transplant Non-anastomotic Strictures.
    Hepatology. 2021 Sep 20. doi: 10.1002/hep.32166.
    >> Share

  143. CARAPETO F, Bozorgui B, Shroff RT, Chagani S, et al
    The Immunogenomic Landscape of Resected Intrahepatic Cholangiocarcinoma.
    Hepatology. 2021 Sep 12. doi: 10.1002/hep.32150.
    >> Share

  144. AN J, Kim D, Oh B, Oh YJ, et al
    Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.
    Hepatology. 2021 Sep 3. doi: 10.1002/hep.32135.
    >> Share

  145. WANG SS, Tang XT, Lin M, Yuan J, et al
    Perivenous Stellate Cells Are the Main Source of Myofibroblasts and Cancer-Associated Fibroblasts Formed After Chronic Liver Injuries.
    Hepatology. 2021;74:1578-1594.
    >> Share

  146. WANG Y, Hylemon PB, Zhou H
    Long Noncoding RNA H19: A Key Player in Liver Diseases.
    Hepatology. 2021;74:1652-1659.
    >> Share

    August 2021
  147. VEDELD HM, Grimsrud MM, Andresen K, Pharo HD, et al
    Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile.
    Hepatology. 2021 Aug 26. doi: 10.1002/hep.32125.
    >> Share

  148. LINDOR KD, Bowlus CL, Boyer J, Levy C, et al
    Primary Biliary Cholangitis: 2021 Practice Guidance Update from the American Association for the Study of Liver Diseases.
    Hepatology. 2021 Aug 24. doi: 10.1002/hep.32117.
    >> Share

  149. ARORA M, Bogenberger JM, Abdelrahman AM, Yonkus J, et al
    Synergistic Combination of Cytotoxic Chemotherapy and Cyclin Dependent Kinase 4/6 Inhibitors in Biliary Tract Cancers.
    Hepatology. 2021 Aug 18. doi: 10.1002/hep.32102.
    >> Share

  150. AMARACHINTHA SP, Mourya R, Ayabe H, Yang L, et al
    Biliary organoids uncover delayed epithelial development and barrier function in biliary atresia.
    Hepatology. 2021 Aug 15. doi: 10.1002/hep.32107.
    >> Share

  151. EL KASMI KC, Ghosh S, Anderson AL, Devereaux MW, et al
    Pharmacologic Activation of Hepatic Farnesoid X Receptor Prevents Parenteral Nutrition Associated Cholestasis in Mice.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32101.
    >> Share

  152. LIN Y, Cai Q, Chen Y, Shi T, et al
    CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma via 5-lipoxygenase.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32099.
    >> Share

  153. ZENG R, Sha W, Leung FW, Chen H, et al
    Letter to the Editor: Proton pump inhibitors and Biliary Tract Cancer Risk: Causality or Reverse Causality?
    Hepatology. 2021 Aug 5. doi: 10.1002/hep.32090.
    >> Share

    July 2021
  154. PANT K, Peixoto E, Richard S, Biswas A, et al
    Histone Deacetylase SIRT1 promotes loss of primary cilia in Cholangiocarcinoma.
    Hepatology. 2021 Jul 29. doi: 10.1002/hep.32080.
    >> Share

  155. CAI P, Mao X, Zhao J, Nie L, et al
    Farnesoid X Receptor is Required for the Redifferentiation of Bi-potential Progenitor Cells during Biliary-Mediated Zebrafish Liver Regeneration.
    Hepatology. 2021 Jul 28. doi: 10.1002/hep.32076.
    >> Share

  156. WADHWANI SI, Gottlieb L, Bucuvalas JC, Lyles C, et al
    Addressing social adversity to improve outcomes for children after liver transplant.
    Hepatology. 2021 Jul 28. doi: 10.1002/hep.32073.
    >> Share

  157. GHOSH S, Devereaux MW, Anderson AL, Gehrke S, et al
    NFkappaB regulation of LRH-1 and ABCG5/8 potentiates phytosterol role in the pathogenesis of parenteral nutrition associated cholestasis.
    Hepatology. 2021 Jul 26. doi: 10.1002/hep.32071.
    >> Share

  158. LOBE C, Vallette M, Arbelaiz A, Gonzalez-Sanchez E, et al
    ZEB1 promotes cholangiocarcinoma progression through tumor dedifferentiation and tumor-stroma paracrine signaling.
    Hepatology. 2021 Jul 23. doi: 10.1002/hep.32069.
    >> Share

  159. ZHANG JW, Yang X, Ding HR, Zhang L, et al
    Is aspirin a drug or just a marker for biliary cancer?
    Hepatology. 2021 Jul 9. doi: 10.1002/hep.32052.
    >> Share

  160. LEE MH, Huang YH, Koshiol J
    Response Letter Regarding Article, "Postdiagnosis aspirin use associated with decreased biliary tract cancer-specific mortality in a large nationwide cohort".
    Hepatology. 2021 Jul 8. doi: 10.1002/hep.32051.
    >> Share

  161. DE GOEIJ FHC, Schlegel A, Muiesan P, Guarrera JV, et al
    Hypothermic oxygenated machine perfusion protects from cholangiopathy in DCD liver transplantation.
    Hepatology. 2021 Jul 7. doi: 10.1002/hep.32044.
    >> Share

  162. WANG H, Song X, Liao H, Wang P, et al
    Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans.
    Hepatology. 2021;74:248-263.
    >> Share

    June 2021
  163. VARTAK N, Drasdo D, Geisler F, Itoh T, et al
    On the mechanisms of biliary flux.
    Hepatology. 2021 Jun 23. doi: 10.1002/hep.32027.
    >> Share

  164. SHI S, Chen S, Verstegen MMA, Pan Q, et al
    Letter to the Editor: HMGB1 Release is a Newly Identified Driver of Inflammation in the Pathogenesis of Biliary Atresia.
    Hepatology. 2021 Jun 23. doi: 10.1002/hep.32026.
    >> Share

  165. MEADOWS V, Kennedy L, Ekser B, Kyritsi K, et al
    Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis via Farnesoid X Receptor Signaling.
    Hepatology. 2021 Jun 23. doi: 10.1002/hep.32028.
    >> Share

  166. BARRON-MILLAR B, Ogle L, Mells G, Flack S, et al
    The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis.
    Hepatology. 2021 Jun 15. doi: 10.1002/hep.32011.
    >> Share

  167. LEE YT, Wang JJ, Luu M, Noureddin M, et al
    Comparison of Clinical Features and Outcomes between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
    Hepatology. 2021 Jun 11. doi: 10.1002/hep.32007.
    >> Share

  168. KYRITSI K, Kennedy L, Meadows V, Hargrove L, et al
    Mast Cells Induce Ductular Reaction Mimicking Liver Injury in Mice Through Mast Cell-Derived Transforming Growth Factor Beta 1 Signaling.
    Hepatology. 2021;73:2397-2410.
    >> Share

    May 2021
  169. LEPORE A, Choy PM, Lee NC, Carella MA, et al
    Phosphorylation and stabilization of PIN1 by JNK promote intrahepatic cholangiocarcinoma growth.
    Hepatology. 2021 May 28. doi: 10.1002/hep.31983.
    >> Share

  170. SUN LY, Hu JY, Liang L, Tong XM, et al
    Letter to the Editor: Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?
    Hepatology. 2021 May 22. doi: 10.1002/hep.31916.
    >> Share

  171. JOHN BV, Deng Y, Martin P, Levy C, et al
    Response to "Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?"
    Hepatology. 2021 May 22. doi: 10.1002/hep.31917.
    >> Share

  172. KAMAL H, Sadr-Azodi O, Engstrand L, Brusselaers N, et al
    Association between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: a Swedish Population-Based Cohort Study.
    Hepatology. 2021 May 21. doi: 10.1002/hep.31914.
    >> Share

  173. MARTINEZ M, Perito ER, Valentino P, Mack CL, et al
    Recurrence of primary sclerosing cholangitis after liver transplant in children: an international observational study.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31911.
    >> Share

  174. JANSSON H, Sparrelid E
    Letter to the Editor: The role of surgery in multiple intrahepatic cholangiocarcinoma should not be dismissed without further analysis.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31905.
    >> Share

  175. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
    Reply to (20-1119.R1) Surgery for advanced intrahepatic cholangiocarcinoma warrants further investigation.
    Hepatology. 2021 May 17. doi: 10.1002/hep.31904.
    >> Share

  176. GENTILINI A, Lori G, Caligiuri A, Raggi C, et al
    Extracellular signal-regulated kinase 5 regulates the malignant phenotype of cholangiocarcinoma cells.
    Hepatology. 2021 May 6. doi: 10.1002/hep.31888.
    >> Share

  177. LIAO SF, Koshiol J, Huang YH, Jackson SS, et al
    Postdiagnosis aspirin use associated with decreased biliary tract cancer-specific mortality in a large nationwide cohort.
    Hepatology. 2021 May 3. doi: 10.1002/hep.31879.
    >> Share

  178. VAN DER LAAN LJW, Roos FJM, Verstegen MMA
    Bile Duct Repair in Human Liver Grafts: Effective Cholangiocyte Organoid Engraftment and Plasticity.
    Hepatology. 2021 May 2. doi: 10.1002/hep.31877.
    >> Share

    April 2021
  179. YOON JG, Kim MH, Jang M, Kim H, et al
    Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and PD-1/PD-L1 Blockade Responses.
    Hepatology. 2021 Apr 21. doi: 10.1002/hep.31862.
    >> Share

  180. XU Y, Leng K, Yao Y, Kang P, et al
    A Circular RNA, Cholangiocarcinoma-Associated Circular RNA 1, Contributes to Cholangiocarcinoma Progression, Induces Angiogenesis, and Disrupts Vascular Endothelial Barriers.
    Hepatology. 2021;73:1419-1435.
    >> Share

  181. OSTROUMOV D, Duong S, Wingerath J, Woller N, et al
    Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
    Hepatology. 2021;73:1399-1418.
    >> Share

    March 2021
  182. DI-LUOFFO M, Pirenne S, Saandi T, Loriot A, et al
    A novel mouse model of cholangiocarcinoma uncovers a role for Tensin-4 in tumor progression.
    Hepatology. 2021 Mar 26. doi: 10.1002/hep.31834.
    >> Share

  183. BOERNER T, Drill E, Pak LM, Nguyen B, et al
    Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
    Hepatology. 2021 Mar 25. doi: 10.1002/hep.31829.
    >> Share

  184. LUO X, Campbell NA, He L, O'Brien DR, et al
    SULF2 monoclonal antibody 5D5 suppresses human cholangiocarcinoma xenograft growth via regulation of a SULF2-PDGFRbeta-YAP signaling axis.
    Hepatology. 2021 Mar 18. doi: 10.1002/hep.31817.
    >> Share

  185. WADA Y, Shimada M, Yamamura K, Toshima T, et al
    A transcriptomic signature for risk-stratification and recurrence prediction in intrahepatic cholangiocarcinoma.
    Hepatology. 2021 Mar 16. doi: 10.1002/hep.31803.
    >> Share

  186. CRISTOFERI L, Calvaruso V, Overi D, Vigano M, et al
    Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naive patients with Primary Biliary Cholangitis: a dual cut-off approach.
    Hepatology. 2021 Mar 16. doi: 10.1002/hep.31810.
    >> Share

  187. KENDRE G, Marhenke S, Lorz G, Becker D, et al
    The co-mutational spectrum determines the therapeutic response in murine FGFR2 fusion - driven cholangiocarcinoma.
    Hepatology. 2021 Mar 11. doi: 10.1002/hep.31799.
    >> Share

  188. VAN WESSEL DBE, Thompson RJ, Gonzales E, Jankowska I, et al
    Impact of Genotype, Serum Bile Acids, and Surgical Biliary Diversion on Native Liver Survival in FIC1 Deficiency.
    Hepatology. 2021 Mar 5. doi: 10.1002/hep.31787.
    >> Share

  189. ZHOU Y, Chen Y, Zhang X, Xu Q, et al
    Brg1 Inhibition Prevents Liver Fibrosis and Cholangiocarcinoma by Attenuating Progenitor Expansion.
    Hepatology. 2021 Mar 2. doi: 10.1002/hep.31780.
    >> Share

    February 2021
  190. CHIU M, Garabon J, Chen L, Karp N, et al
    Mevalonic Aciduria Associated with Intrahepatic Bile Duct Paucity.
    Hepatology. 2021 Feb 27. doi: 10.1002/hep.31778.
    >> Share

  191. JOHNSON KM, Fischer RT, Holtmann GJ, Shah A, et al
    Letter to the editor: Oral vancomycin versus no therapy for pediatric primary sclerosing cholangitis.
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31764.
    >> Share

  192. SHIOTA J, Samuelson LC, Razumilava N
    Hepatobiliary organoids and their applications for studies of liver health and disease: are we there yet?
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31772.
    >> Share

  193. JOHN BV, Aitcheson G, Schwartz KB, Shabbir Khakoo N, et al
    Male Gender is Associated with Higher Rates of Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis.
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31776.
    >> Share

  194. DAT NQ, Thuy LTT, Hieu VN, Hai H, et al
    6His-tagged Recombinant Human Cytoglobin Deactivates Hepatic Stellate Cells and Inhibits Liver Fibrosis by Scavenging Reactive Oxygen Species.
    Hepatology. 2021 Feb 11. doi: 10.1002/hep.31752.
    >> Share

  195. MOHANTY SK, Donnelly B, Temple H, Ortiz-Perez A, et al
    HMGB1 release by cholangiocytes governs biliary atresia pathogenesis and correlates with increases in afflicted infants.
    Hepatology. 2021 Feb 8. doi: 10.1002/hep.31745.
    >> Share

  196. JAVITT NB
    Letter to the Editor: Intravital dynamic and correlative imaging reveals diffusion-dominated canalicular and flow-augmented ductular bile flux.
    Hepatology. 2021 Feb 8. doi: 10.1002/hep.31746.
    >> Share

  197. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
    Reply to "Does multiple intrahepatic cholangiocarcinoma worsen prognosis as "M1" stage?"; multiple primaries vs liver metastases.
    Hepatology. 2021 Feb 7. doi: 10.1002/hep.31740.
    >> Share

  198. ZHANG XF, Lv Y, Pawlik TM
    Letter to the editor: Does multiple intrahepatic cholangiocarcinoma worsen prognosis as "M1" stage?
    Hepatology. 2021 Feb 6. doi: 10.1002/hep.31741.
    >> Share

  199. NASSER-GHODSI N, Mara K, Watt KD
    De novo Colorectal and Pancreatic Cancer in Liver Transplant Recipients: Identifying the Higher Risk Populations.
    Hepatology. 2021 Feb 5. doi: 10.1002/hep.31731.
    >> Share

    January 2021
  200. ITOH A, Adams D, Huang W, Wu Y, et al
    Enoxacin upregulates microRNA biogenesis and downregulates cytotoxic CD8 T cell function in autoimmune cholangitis.
    Hepatology. 2021 Jan 19. doi: 10.1002/hep.31724.
    >> Share

  201. LI J, Ye X, He S
    Letter to the Editor: Imaging monitoring of primary sclerosing cholangitis patients.
    Hepatology. 2021 Jan 11. doi: 10.1002/hep.31709.
    >> Share

  202. ASSIS DN, Levy C
    Oral Vancomycin or Ursodeoxycholic acid for Pediatric Primary Sclerosing Cholangitis? The Uncontroversial Need for Randomized Controlled Trials.
    Hepatology. 2021 Jan 5. doi: 10.1002/hep.31702.
    >> Share

  203. FENG GS, Hanley KL, Liang Y, Lin X, et al
    Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies.
    Hepatology. 2021;73 Suppl 1:104-114.
    >> Share

  204. RIZVI S, Wang J, El-Khoueiry AB
    Liver Cancer Immunity.
    Hepatology. 2021;73 Suppl 1:86-103.
    >> Share

  205. LU X, Paliogiannis P, Calvisi DF, Chen X, et al
    Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies.
    Hepatology. 2021;73 Suppl 1:49-61.
    >> Share

    December 2020
  206. KOUKOULIOTI E, Ziagaki A, Weber SN, Lammert F, et al
    Long-term colestyramine treatment prevents cholestatic attacks in refractory benign recurrent intrahepatic cholestasis type 1 disease.
    Hepatology. 2020 Dec 5. doi: 10.1002/hep.31671.
    >> Share

    November 2020
  207. KNOOIHUIZEN SAI, Aday A, Lee WM
    Ketamine-Induced Sclerosing Cholangitis (KISC) in a Critically Ill Patient with COVID-19.
    Hepatology. 2020 Nov 23. doi: 10.1002/hep.31650.
    >> Share

  208. MOUSA OY, Juran BD, McCauley BM, Vesterhus MN, et al
    Bile Acid Profiles in Primary Sclerosing Cholangitis and their Ability to Predict Hepatic Decompensation.
    Hepatology. 2020 Nov 23. doi: 10.1002/hep.31652.
    >> Share

  209. KUNST RF, Verkade HJ, Oude Elferink RPJ, van de Graaf SFJ, et al
    Targeting the four pillars of enterohepatic bile salt cycling; lessons from genetics and pharmacology.
    Hepatology. 2020 Nov 22. doi: 10.1002/hep.31651.
    >> Share

  210. SATO K, Zhang W, Safarikia S, Isidan A, et al
    Organoids and spheroids as novel models for studying cholestatic liver injury and cholangiocarcinoma.
    Hepatology. 2020 Nov 22. doi: 10.1002/hep.31653.
    >> Share

  211. COLYN L, Barcena-Varela M, Alvarez-Sola G, Latasa MU, et al
    Dual targeting of G9a and DNMT1 for the treatment of experimental cholangiocarcinoma.
    Hepatology. 2020 Nov 22. doi: 10.1002/hep.31642.
    >> Share

  212. MEADOWS V, Francis H
    DCLK1 in Cholangiocarcinoma: Is this the biomarker and target we've been looking for?
    Hepatology. 2020 Nov 11. doi: 10.1002/hep.31630.
    >> Share

  213. SMETS L, Verbeek J, Korf H, van der Merwe S, et al
    Improved markers of cholestatic liver injury in patients with primary biliary cholangitis treated with obeticholic acid and bezafibrate.
    Hepatology. 2020 Nov 3. doi: 10.1002/hep.31613.
    >> Share

    October 2020
  214. XU Y, Zhu Y, Hu S, Xu Y, et al
    Hepatocyte nuclear factor 4alpha prevents the steatosis-to-NASH progression by regulating p53 and bile acid signaling.
    Hepatology. 2020 Oct 23. doi: 10.1002/hep.31604.
    >> Share

  215. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
    Liver metastases of intrahepatic cholangiocarcinoma: implications for a potential new staging system.
    Hepatology. 2020 Oct 18. doi: 10.1002/hep.31598.
    >> Share

  216. BRAGELMANN J, Barahona Ponce C, Marcelain K, Roessler S, et al
    Epigenome-wide analysis of methylation changes in the sequence of gallstone disease, dysplasia, and gallbladder cancer.
    Hepatology. 2020 Oct 5. doi: 10.1002/hep.31585.
    >> Share

  217. KUNZMANN LK, Schoknecht T, Poch T, Henze L, et al
    Monocytes as Potential Mediators of Pathogen-Induced T-Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC).
    Hepatology. 2020;72:1310-1326.
    >> Share

    September 2020
  218. NEVI L, Di Matteo S, Carpino G, Zizzari I, et al
    DCLK1, a putative novel stem cell marker in human cholangiocarcinoma.
    Hepatology. 2020 Sep 25. doi: 10.1002/hep.31571.
    >> Share

  219. EATON JE, Welle CL, Bakhshi Z, Sheedy SP, et al
    Early cholangiocarcinoma detection with magnetic resonance imaging versus ultrasound in primary sclerosing cholangitis.
    Hepatology. 2020 Sep 25. doi: 10.1002/hep.31575.
    >> Share

    August 2020
  220. LEUNG KK, James PD, Jaberi A, Hirschfield GM, et al
    Esophageal Stenting as Bridge Therapy to Direct Intrahepatic Portocaval Shunt for Refractory Variceal Bleeding.
    Hepatology. 2020 Aug 11. doi: 10.1002/hep.31519.
    >> Share

    July 2020
  221. DU Y, Khandekar G, Llewellyn J, Polacheck W, et al
    Reply to letter to the editor: Comment on "a bile duct-on-a-chip with organ-level functions".
    Hepatology. 2020 Jul 21. doi: 10.1002/hep.31471.
    >> Share

  222. SCHULTHEISS C, Simnica D, Willscher E, Oberle A, et al
    Next-generation immunosequencing reveals pathological T cell architecture in autoimmune hepatitis.
    Hepatology. 2020 Jul 21. doi: 10.1002/hep.31473.
    >> Share

  223. LLEO A, Ma X, Gershwin ME, Invernizzi P, et al
    Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?
    Hepatology. 2020;72:359-360.
    >> Share

    April 2020
  224. ADAMS JM, Huppert KA, Castro EC, Lopez MF, et al
    Sox9 Is a Modifier of the Liver Disease Severity in a Mouse Model of Alagille Syndrome.
    Hepatology. 2020;71:1331-1349.
    >> Share

    March 2020
  225. LU ZN, Luo Q, Zhao LN, Shi Y, et al
    The Mutational Features of Aristolochic Acid-Induced Mouse and Human Liver Cancers.
    Hepatology. 2020;71:929-942.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016